Earnings per Share (EPS) of -0.02, surpassing the estimated EPS of -0.03.
Reported revenue was approximately $206,329.46, in line with expectations.
Positive financial indicators include a low debt-to-equity ratio of 0.14 and a current ratio of 4.87.
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) is a company focused on developing and selling biological solutions for agriculture. Its flagship product, TerraSante, is a biofertility product aimed at enhancing crop yields. The company operates in a competitive market, with other players also offering innovative agricultural solutions. MGROF trades on the PNK exchange.
On November 26, 2024, MGROF reported its earnings, revealing an earnings per share (EPS) of -0.02, which surpassed the estimated EPS of -0.03. The company’s revenue was approximately $206,329.46, aligning with expectations. This performance reflects the initial revenue from TerraSante sales, which amounted to C$279,000, including C$272,000 in deferred revenue.
Despite a negative price-to-earnings (P/E) ratio of -209.88, MGROF’s financial metrics show some positive aspects. The debt-to-equity ratio is low at 0.14, indicating limited reliance on debt. Additionally, the current ratio of 4.87 suggests a strong ability to meet short-term obligations, providing a cushion for the company as it navigates its growth phase.
Analysts at Noble Capital are optimistic about MGROF’s future, projecting a significant increase in TerraSante sales for 2025. They expect fourth-quarter revenue to be around C$25,000, with a target of C$625,000 for fiscal 2025. This growth is anticipated as the company secures more state approvals, expanding its market reach.
The enterprise value to sales ratio of 18.00 and the price-to-sales ratio of 18.88 indicate that investors are willing to pay a premium for MGROF’s sales, reflecting confidence in its growth potential. However, the enterprise value to operating cash flow ratio is significantly negative at -453.31, highlighting challenges in generating cash flow.
